Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion Pharmaceuticals (NASDAQ: RXRX) announced the approval of inducement restricted stock unit (RSU) awards by its Board's Compensation Committee on December 19, 2024. The grants cover 7,952,836 shares of class A common stock, distributed among 230 new employees under the company's 2024 Inducement Equity Incentive Plan. These awards were granted in connection with Recursion's acquisition of Exscientia plc. The RSUs will vest quarterly at a rate of 1/16th of shares on February 15, May 15, August 15, and November 15, starting February 15, 2025, contingent on continued employment.
Recursion Pharmaceuticals (NASDAQ: RXRX) ha annunciato l'approvazione da parte del Comitato per la Compensazione del Consiglio di Amministrazione di premi sotto forma di unità azionarie a titolo di incentivo (RSU) il 19 dicembre 2024. I conferimenti riguardano 7.952.836 azioni di classe A di azioni ordinarie, distribuite tra 230 nuovi dipendenti nell'ambito del Piano di Incentivazione Azionaria di Induzione 2024 dell'azienda. Questi premi sono stati concessi in relazione all'acquisizione di Exscientia plc da parte di Recursion. Le RSU matureranno trimestralmente a una rate di 1/16 delle azioni il 15 febbraio, 15 maggio, 15 agosto e 15 novembre, a partire dal 15 febbraio 2025, a condizione del mantenimento dell'impiego.
Recursion Pharmaceuticals (NASDAQ: RXRX) anunció la aprobación de premios en forma de unidades de acciones restringidas como incentivo (RSU) por parte del Comité de Compensación de su Junta el 19 de diciembre de 2024. Los premios cubren 7,952,836 acciones de acciones ordinarias clase A, distribuidas entre 230 nuevos empleados bajo el Plan de Incentivo de Capital de Inducción 2024 de la compañía. Estos premios fueron otorgados en relación con la adquisición de Exscientia plc por parte de Recursion. Las RSU se consolidarán trimestralmente a una tasa de 1/16 de las acciones el 15 de febrero, 15 de mayo, 15 de agosto y 15 de noviembre, comenzando el 15 de febrero de 2025, condicionadas al empleo continuado.
Recursion Pharmaceuticals (NASDAQ: RXRX)는 2024년 12월 19일 이사회 보상위원회에서 유도 제한 주식 단위(RSU) 보상을 승인했다고 발표했습니다. 이 보상은 7,952,836주의 A 클래스 보통주를 포함하며, 2024년 회사의 유도 주식 인센티브 플랜 하에 230명의 신입 사원에게 분배됩니다. 이 보상은 Recursion이 Exscientia plc를 인수하는 것과 관련하여 수여되었습니다. RSU는 2025년 2월 15일부터 시작하여 계속 고용될 경우 2월 15일, 5월 15일, 8월 15일, 11월 15일에 각각 1/16의 비율로 분기마다 적용됩니다.
Recursion Pharmaceuticals (NASDAQ: RXRX) a annoncé l'approbation par le Comité de Rémunération de son Conseil d'Administration de l'attribution d'unités d'actions restreintes (RSU) en date du 19 décembre 2024. Les attributions couvrent 7 952 836 actions ordinaires de classe A, réparties parmi 230 nouveaux employés dans le cadre du Plan d'Incitation au Capital d'Induction 2024 de l'entreprise. Ces attributions ont été accordées en lien avec l'acquisition d'Exscientia plc par Recursion. Les RSU se verront attribuer trimestriellement à raison de 1/16 des actions le 15 février, le 15 mai, le 15 août et le 15 novembre, à compter du 15 février 2025, sous réserve de maintien de l'emploi.
Recursion Pharmaceuticals (NASDAQ: RXRX) gab am 19. Dezember 2024 bekannt, dass der Vergütungsausschuss des Vorstands die Genehmigung von Anreizzahlungen in Form von Restricted Stock Units (RSU) erteilt hat. Die Vergaben umfassen 7.952.836 Aktien der Klasse A, verteilt auf 230 neue Mitarbeiter im Rahmen des Anreiz-Aktienplans 2024 des Unternehmens. Diese Auszeichnungen wurden im Zusammenhang mit der Übernahme von Exscientia plc durch Recursion vergeben. Die RSUs werden vierteljährlich zu einem Satz von 1/16 der Aktien am 15. Februar, 15. Mai, 15. August und 15. November, beginnend am 15. Februar 2025, und unter der Voraussetzung einer fortgesetzten Beschäftigung fällig.
- Successful integration of Exscientia acquisition with retention strategy through RSU grants
- Significant expansion of workforce with 230 new employees
- Potential dilution of existing shareholders due to issuance of 7.95M new shares
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4).
Each inducement RSU award will vest as to 1/16th of the shares subject to the award quarterly on each of February 15, May 15, August 15, and November 15, beginning with February 15, 2025 until the inducement RSU award is fully vested, subject to the inducement RSU award recipient’s continued employment through the Company Vesting Dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
FAQ
How many shares are included in RXRX's December 2024 inducement RSU awards?
What is the vesting schedule for RXRX's 2024 inducement RSU awards?
How many new employees received RXRX inducement awards in December 2024?
Why did Recursion Pharmaceuticals (RXRX) issue these inducement awards?
